HUTCHMED

— 公司啟動索凡替尼一期臨床試驗和黃醫藥宣布啟動其治療癌症的全新候選藥物索凡替尼的I 期臨床研究，第一例受試者於近日開始用藥。索凡替尼的新藥臨床試驗申請通過國家藥品食品

Interim Results for the Six Months Ended 30 June 2011

China Healthcare Division expands OTC drug distribution and marketing operations

Notice of Announcement of 2011 Interim Results

Blocklisting Six Monthly Return

TR-1: Notification of major interests in shares

TR-1: Notification of major interests in shares

Results of Annual General Meeting

AACR 2011: Savolitinib (HMPL-504) against subcutaneous xenograft and orthotopic brain tumor models

2010 Annual Report and Notice of Annual General Meeting

Director's Shareholding

Final Results for the year ended 31 December 2010 Strong performance across all divisions.

Board Change

Appointment of UBS Limited as Joint Broker

和黃醫藥獲SFDA批准啟動呋喹替尼一期臨床研究

Notice of Announcement of 2010 Final Results

Total Voting Rights

Blocklisting Six Monthly Return

Hutchison MediPharma Receives Further Strategic Investment to Advance Its Pipeline

China Healthcare Division Chi-Med increases indirect ownership of its Hutchison Baiyunshan joint venture

Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis – a double-blind comparison with sustained release mesalazine (Alimentary Pharmacology and Therapeutics 2011)

Hutchison MediPharma Receives Strategic Investment to Advance Its Pipeline

ISSX 2011: Preclinical assessment of the absorption, distribution, metabolism and excretion of HMPL-013 (fruquintinib), a novel potent and specific VEGFR inhibitor

Hutchison Hain Organic launch EARTH'S BEST® and ZHI LING TONG Co-branded Infant formula in China

Appointment of Joint Broker

Interim Results for the Six Months Ended 30 June 2010 Strong results. Continued momentum. Positive outlook.

TR-1: Notification of major interests in shares

Notice of Announcement of 2010 Interim Results

TR-1: Notification of major interests in shares

Total Voting Rights

Blocklisting Six Monthly Return

Director's Shareholding

TR-1: Notification of major interests in shares

和黃醫藥抗癌新藥索凡替尼獲得國家藥監局新藥臨床試驗批文

Results of Annual General Meeting

Seven-year extension of IP protection for Chi-Med's main prescription drug

2009 Annual Report and Notice of Annual General Meeting

TR-1: Notification of major interests in shares

TR-1: Notification of major interests in shares

TR-1: Notification of major interests in shares

TR-1: Notification of Major Interests in Shares

Final Results for the year ended 31 December 2009

Notice of Announcement of 2009 Final Results

Total Voting Rights

Three more of Chi-Med's China Healthcare Division drugs added to latest China's National Medicines Catalogue

Total Voting Rights

Blocklisting Six Monthly Return

TR-1 : Notification of Major Interests in Shares

Successful Global Phase IIb Ulcerative Colitis Trial for HMPL-004: All Primary and Secondary Endpoints Achieved Hutchison MediPharma Proceeding with Development and Partnership Plans

和黃醫藥（上海）有限公司啟動治療自身免疫病的全新侯選藥物HMPL-011的一期臨床試驗

Chi-Med increases ownership of its Hutchison Healthcare joint venture to 100%